New Rabbit Model Enables Epstein-Barr Virus Study
Researchers successfully infect immunosuppressed rabbits with EBV, providing a new platform to study the viral lifecycle.
Updated on Oct. 27, 2026 in Life Sciences
Researchers have established a rabbit model for studying Epstein-Barr virus (EBV) infection. This research-stage study demonstrates that immunosuppressed rabbits infected with EBV develop splenomegaly and altered spleen follicle formation.
Why it matters
This model provides a new experimental pathway to investigate the EBV lifecycle in B cells and epithelial cells. Because the virus infects over 90% of the global population, identifying reliable animal models is essential for understanding how the pathogen persists and replicates within the host.
Immunosuppressed rabbits infected with B95-8 and Akata viral strains produced antibodies to EBNA proteins, with Akata strains yielding more consistent results. Immunocompetent rabbits showed no significant changes in spleen morphology compared to mock-infected controls.
The players
Journal of Virology
A peer-reviewed scientific publication managed by the American Society for Microbiology that focuses on the mechanisms of viral infection and replication.
The details
The model involves infecting immunosuppressed rabbits with Epstein-Barr virus to observe pathological changes in the spleen, a primary organ for immune response. Researchers measured the formation of spleen follicles—organized clusters of immune cells—and antibody responses against the EBNA (Epstein-Barr nuclear antigen) family of proteins. These findings suggest the rabbit model can effectively replicate specific features of EBV pathogenesis under suppressed immune conditions.
Timeline
- 2026-10-27
The research study was published in the Journal of Virology.
The Tech Race
Developing small animal models for Epstein-Barr virus is a critical hurdle in virology research, as the virus does not easily replicate in standard laboratory models. This rabbit model provides a new tool to study pathogen interaction, moving beyond the reliance on non-human primates.
This development is currently in the research phase and does not change clinical protocols for patients. Scientists will use this model to further examine viral persistence and potential therapeutic targets for EBV-related conditions.
The takeaway
The study offers a viable platform to study EBV, though researchers must still demonstrate whether the virus can sustain its full lifecycle in this model. Future studies will focus on long-term viral persistence to confirm if this platform can support preclinical testing for new treatments.
Further reading
For broader trends in virology and experimental pathology, see our coverage in Life Sciences.
More information
Review the technical findings in the Journal of Virology research article.
Source note: This article includes information reported by Journal of Virology.
